Literature DB >> 26552970

Ertapenem-Containing Double-Carbapenem Therapy for Treatment of Infections Caused by Carbapenem-Resistant Klebsiella pneumoniae.

Jessica B Cprek1, Jason C Gallagher2.   

Abstract

We describe outcomes of patients with infections with carbapenem-resistant Klebsiella pneumoniae (CRKP) who received ertapenem-containing double-carbapenem therapy (ECDCT). Clinical success was observed in 7/18 (39%) patients overall: bloodstream infections, 3/7 (43%); pneumonia, 1/5 (20%); intraabdominal infections, 0/2 (0%); urinary tract infections, 2/3 (67%); and a skin and skin structure infection, 1/1 (100%). Microbiologic success was observed in 11/14 (79%) evaluable patients; 5/18 (28%) patients died. ECDCT may be effective for CRKP infections with limited treatment options.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26552970      PMCID： PMC4704223          DOI： 10.1128/AAC.01569-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients.

Authors:  Mahesh N Samtani; Robert Flamm; Koné Kaniga; Partha Nandy
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

2.  CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting.

Authors:  Teresa C Horan; Mary Andrus; Margaret A Dudeck
Journal:  Am J Infect Control       Date:  2008-06       Impact factor: 2.918

3.  Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay.

Authors:  Spyros Pournaras; Georgia Vrioni; Evangelia Neou; John Dendrinos; Evangelia Dimitroulia; Aggeliki Poulou; Athanassios Tsakris
Journal:  Int J Antimicrob Agents       Date:  2011-01-13       Impact factor: 5.283

4.  Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae.

Authors:  H Yigit; A M Queenan; G J Anderson; A Domenech-Sanchez; J W Biddle; C D Steward; S Alberti; K Bush; F C Tenover
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

5.  Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns.

Authors:  Khetam Hussein; Hanna Sprecher; Tania Mashiach; Ilana Oren; Imad Kassis; Renato Finkelstein
Journal:  Infect Control Hosp Epidemiol       Date:  2009-07       Impact factor: 3.254

6.  Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.

Authors:  Jason A Roberts; Carl M J Kirkpatrick; Michael S Roberts; Thomas A Robertson; Andrew J Dalley; Jeffrey Lipman
Journal:  J Antimicrob Chemother       Date:  2009-04-27       Impact factor: 5.790

Review 7.  The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria.

Authors:  Patrice Nordmann; Gaelle Cuzon; Thierry Naas
Journal:  Lancet Infect Dis       Date:  2009-04       Impact factor: 25.071

8.  Validation of a combined comorbidity index.

Authors:  M Charlson; T P Szatrowski; J Peterson; J Gold
Journal:  J Clin Epidemiol       Date:  1994-11       Impact factor: 6.437

9.  Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteriaceae.

Authors:  K F Anderson; D R Lonsway; J K Rasheed; J Biddle; B Jensen; L K McDougal; R B Carey; A Thompson; S Stocker; B Limbago; J B Patel
Journal:  J Clin Microbiol       Date:  2007-06-20       Impact factor: 5.948

Review 10.  Aminoglycosides: nephrotoxicity.

Authors:  M P Mingeot-Leclercq; P M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191
View more
  19 in total

Review 1.  Pharmacodynamic and pharmacokinetic considerations in the treatment of critically Ill patients infected with carbapenem-resistant Enterobacteriaceae.

Authors:  Elizabeth A Neuner; Jason C Gallagher
Journal:  Virulence       Date:  2016-08-09       Impact factor: 5.882

2.  Double-carbapenem combination as salvage therapy for untreatable infections by KPC-2-producing Klebsiella pneumoniae.

Authors:  M Souli; I Karaiskos; A Masgala; L Galani; E Barmpouti; H Giamarellou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-02-16       Impact factor: 3.267

3.  Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms.

Authors:  Elizabeth Temkin; Julian Torre-Cisneros; Bojana Beovic; Natividad Benito; Maddalena Giannella; Raúl Gilarranz; Cameron Jeremiah; Belén Loeches; Isabel Machuca; María José Jiménez-Martín; José Antonio Martínez; Marta Mora-Rillo; Enrique Navas; Michael Osthoff; Juan Carlos Pozo; Juan Carlos Ramos Ramos; Marina Rodriguez; Miguel Sánchez-García; Pierluigi Viale; Michel Wolff; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

Review 4.  Therapeutic options for carbapenem-resistant Enterobacteriaceae infections.

Authors:  Enrico Maria Trecarichi; Mario Tumbarello
Journal:  Virulence       Date:  2017-02-08       Impact factor: 5.882

Review 5.  The Epidemiology, Evolution, and Treatment of KPC-Producing Organisms.

Authors:  Ann Marie Porreca; Kaede V Sullivan; Jason C Gallagher
Journal:  Curr Infect Dis Rep       Date:  2018-05-05       Impact factor: 3.725

6.  XDR-Klebsiella pneumoniae isolates harboring blaOXA-48: In vitro and in vivo evaluation using a murine thigh-infection model.

Authors:  Noha A Kamel; Wafaa N El-Tayeb; Mona R El-Ansary; Mohamed T Mansour; Khaled M Aboshanab
Journal:  Exp Biol Med (Maywood)       Date:  2019-10-31

7.  Comparative pharmacodynamics of four different carbapenems in combination with polymyxin B against carbapenem-resistant Acinetobacter baumannii.

Authors:  Justin R Lenhard; Jonathan S Gall; Jurgen B Bulitta; Visanu Thamlikitkul; Cornelia B Landersdorfer; Alan Forrest; Roger L Nation; Jian Li; Brian T Tsuji
Journal:  Int J Antimicrob Agents       Date:  2016-09-20       Impact factor: 5.283

Review 8.  Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.

Authors:  Jesús Rodríguez-Baño; Belén Gutiérrez-Gutiérrez; Isabel Machuca; Alvaro Pascual
Journal:  Clin Microbiol Rev       Date:  2018-02-14       Impact factor: 26.132

Review 9.  Treatment Options for Carbapenem- Resistant Gram-Negative Infections.

Authors:  Moritz Fritzenwanker; Can Imirzalioglu; Susanne Herold; Florian M Wagenlehner; Klaus-Peter Zimmer; Trinad Chakraborty
Journal:  Dtsch Arztebl Int       Date:  2018-05-21       Impact factor: 5.594

Review 10.  The rapid spread of carbapenem-resistant Enterobacteriaceae.

Authors:  Robert F Potter; Alaric W D'Souza; Gautam Dantas
Journal:  Drug Resist Updat       Date:  2016-09-19       Impact factor: 18.500
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.